New inhaled drug RB042 enters first human safety tests

NCT ID NCT07285122

Recruiting now Knowledge-focused Sponsor: Atisama Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study is testing an inhaled drug called RB042 for the first time in humans. Researchers want to see if it is safe and how the body handles it. The study includes 90 healthy adults, some of whom are smokers. Participants will receive either RB042 or a placebo through a nebulizer. This research does not aim to treat any disease but to gather essential safety data.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RB042
What could go wrong: This is a very early phase 1 study in healthy people, not patients. It only tests safety and how the drug moves through the body, not whether it works for any disease. Many drugs fail at this stage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY HEALTHY SMOKER

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Linear Clinical Research
RECRUITING

Nedlands, Western Australia, 6009, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.